There is no standard treatment for radiation dermatitis. In this study, the investigators have designed novel ROS-scavenging nanoenzymes and aim to evaluate their effectiveness in preventing radiation dermatitis in patients with head and neck cancer.
Radiotherapy often leads to various complications, with radiation dermatitis being the most common side effect observed in the majority of tumor patients undergoing treatment. This condition not only affects a patient's appearance but, in severe cases, may even require the interruption of treatment. Currently, there is no standard treatment for radiation dermatitis. In this study, the investigators have designed novel ROS-scavenging nanoenzymes, offering a potential new approach for preventing and treating radiation dermatitis. This clinical trial aims to evaluate the effectiveness of these novel ROS-scavenging nanoenzymes in preventing radiation dermatitis in patients with head and neck cancer.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
30
ROS-scavenging nanoenzymes are applied to the treatment area, once daily during radiotherapy.
Standard of care
West China Hospital, Sichuan University
Chengdu, Sichuan, China
RECRUITINGThe incidence of grade 2 or higher radiation dermatitis
Patients are assessed weekly for radiation dermatitis by an experienced radiation oncology nurse according to the Radiation Therapy Oncology Group (RTOG) criteria.
Time frame: From the start of radiotherapy to 2 weeks after completion of radiotherapy.
The maximum skin toxicity
The maximum grade of RTOG skin toxicity between 0 and 4.
Time frame: From the start of radiotherapy to 2 weeks after completion of radiotherapy.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.